Showing 1101-1110 of 1614 results for "".
- Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45 Million Public Offering of Common Stockhttps://modernod.com/news/aerpio-pharmaceuticals-announces-uplisting-to-nasdaq-capital-market-and-pricing-of-45-million-public-offering-of-common-stock/2480066/Aerpio Pharmaceuticals announced that its common stock will begin trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018, following its previously announced approval to list its common stock on the Nasdaq Capital Market. Aerpio also announce
- Market Scope: New Products Poised to Drive Glaucoma Pharma Market to $6.6 Billion by 2023https://modernod.com/news/market-scope-new-products-poised-to-drive-glaucoma-pharma-market-to-6-6-billion-by-2023/2480067/The launches of Vyzulta, Rhopressa, and preservative-free formulations promise to boost manufacturers’ revenues during the next 5 years in the global glaucoma pharmaceuticals market. The upswing follows years of declining revenues as branded products lost patent protection and the market s
- Ophthalmic OR Microscope Market to See More Than 6 Percent Growth over Next Five Yearshttps://modernod.com/news/ophthalmic-or-microscope-market-to-see-more-than-6-percent-growth-over-next-five-years/2480110/Market Scope expects the global ophthalmic operating room (OR) microscope market to grow at a healthy pace of more than 6 percent over the next 5 years, as 2018 revenues of $403 million climb to nearly $548 million by 2023. Revenues will rise most sharply in Latin America and other develop
- Market Scope: China’s Ophthalmic Market to grow 11.3% to $4.5 Billion in 2023https://modernod.com/news/market-scope-chinas-ophthalmic-market-to-grow-11-3-to-4-5-billion-in-2023/2480211/Market Scope forecasts that China’s $2.6 billion ophthalmic market will grow at a compound annual rate of 11.3 percent over the next 5 years to $4.5 billion in 2023. China has tremendous unmet need for ophthalmic care. The country is home to approximately one-third of the world’s blind peo
- Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatanhttps://modernod.com/news/aerie-pharmaceuticals-announces-appointment-of-scott-laranjo-as-director-marketing-roclatan/2480254/Aerie Pharmaceuticals announced the appointment of Scott Laranjo as Director, Marketing, Roclatan, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Mr. Laranjo will direct future marketing activities associated with Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005
- FDA Approves Marketing For First AI Device for Diabetic Retinopathy Detectionhttps://modernod.com/news/fda-permits-marketing-of-ai-based-device-to-detect-certain-diabetes-related-eye-problems/2480256/The FDA has permitted marketing for the first medical device to use artificial intelligence to detect greater than a mild level of diabetic retinopathy in adults who have diabetes. The device, called IDx-DR, is a software program that uses an artificial intelligence algorithm to analyze im
- Market Scope: Patient Demand for Better Vision Will Drive Double-Digit Growth in IOL Revenueshttps://modernod.com/news/patient-demand-for-better-vision-will-drive-double-digit-growth-in-iol-revenues/2480268/Technological innovations in premium IOLs will help drive global IOL revenues to more than $6.1 billion by 2023, according to Market Scope data.
- Avisi Technologies Announces Positive 12-Month Clinical Data on VisiPlate Aqueous Shunthttps://modernod.com/news/avisi-technologies-announces-positive-12-month-clinical-data-on-visiplate-aqueous-shunt/2484305/Avisi Technologies announced positive 12-month clinical data on its VisiPlate Aqueous Shunt from the VITA trial during the 2025 AAO Annual Meeting. The study was presented by Jonathan Myers, MD, chief of the glaucoma service at Wills Eye Hospital, Thomas Jefferson University, in Philadelphia.
- Navigate Patient Solutions Adds Ophthalmology Leaders to its Medical Advisory Boardhttps://modernod.com/news/navigate-patient-solutions-adds-ophthalmology-leaders-to-its-medical-advisory-board/2482835/Navigate Patient Solutions announced the addition of Vance Thompson, MD; David Cox, and Matthew P. Jensen to its Medical Advisory Board. Navigate is developing a patient engagement solution for ophthalmology. The startup partners with ophthal
- CIRM Awards $4.7 Million for Vision Loss Gene Therapyhttps://modernod.com/news/cirm-awards-47-million-for-vision-loss-gene-therapy/2482827/The California Institute for Regenerative Medicine (CIRM) awarded $4.7 million to Blue Gen Therapeutics Foundation (Principal Investigator Aaron Nagiel, MD, PhD) to fund preclinical research that aims to develop a gene therapy for the rare disease blue cone monochromacy (BCM). <